Sponsored Content

Regenerative medicine company, Regeneus (ASX: RGS), has reported positive results from a study that tested the efficacy of its Sygenus gel on the appearance of age spots.

Sygenus is a patented allogenic cell secretions technology platform, comprising cytokines, growth factors and exosomes from fat-derived mesenchymal stem cells (MSCs). Its cells have been shown to reduce pain and inflammation and encourage accelerated healing and repair.

Age spots are caused by an overproduction of melanin in the skin due to cellular damage from overexposure to the sun.  The cellular damage leads to the release of inflammatory cytokines that drive the overproduction of melanin.

The anti-inflammatory and immunomodulatory capabilities of the Sygenus gel appear to reverse this inflammatory cycle.

The study was conducted on 36 healthy, female volunteers over the age of 35 to measure the effectiveness of the Sygenus gel in reducing the colour and size of age spots.

The subjects applied the gel twice daily for a period of eight weeks and were evaluated after four and eight weeks of use. At eight weeks, the results showed that 95 percent of age spots were smaller, and 63 percent of age spots were both smaller and lighter.

Regeneus CEO John Martin was thrilled with the positive results from the study, highlighting the multiple applications for Sygenus.

“This is a fantastic outcome for our Sygenus technology, and demonstrates its strong potential to address multiple indications, both cosmetic and therapeutic in nature.”

“The Regeneus team continues to further develop the Sygenus technology, with additional specific pain and dermatological indications identified for which Sygenus could prove a potential treatment.”

The results highlight the potential of the Sygenus platform which has already been shown to significantly reduce the appearance of acne lesions.

Sygenus has also been shown to have potential therapeutic applications, delivering significantly longer lasting analgesic effects from topical application than an injection of morphine in a pre-clinical, post-operative pain study.

Mr Martin added, “we continue to further develop the Sygenus platform and we are exploring the potential for additional applications of the technology.”

Regeneus has been granted a broad Australian patent for the topical application of Sygenus in the treatment of aging skin and age spots.

The patent covers topical application for the treatment of dry skin, wrinkling of the skin, thin skin, cracking of the skin, stretch marks, sun spots, age spots, liver spots, puffiness and/or dark circles around the eyes.

The patent further extends the Regeneus patent portfolio to 80 patents or patent applications across 14 patent families, and a total of 12 patents granted in Australia.

 

This content is produced by Star Investing in commercial partnership with Regeneus.  This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.